title: Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study.
abstract: BACKGROUND
  Weight loss among older patients is a severe problem, associated with an increased incidence of infections, decubiti, and death. Megestrol acetate (MA) causes weight gain in cachectic cancer and AIDS patients, but its effects in older cachectic patients are unknown.
  
  
  OBJECTIVE
  To compare the effects of MA oral suspension (O.S.), 800 mg/day, versus placebo on weight in geriatric nursing home patients with weight loss or low body weight.
  
  
  METHODS
  Twelve-week, randomized, double-blind, placebo-controlled trial with a 13-week follow-up period.
  
  
  METHODS
  Veterans Administration Medical Center (VMAC) nursing home.
  
  
  METHODS
  Nursing home patients with weight loss of > or =5% of usual body weight over the past 3 months, or body weight 20% below their ideal body weight.
  
  
  METHODS
  Patients were randomly assigned to receive placebo or MA 800 mg/day for 12 weeks and were then followed for 13 weeks off treatment.
  
  
  METHODS
  Primary outcome was measured by weight and appetite change. Secondary outcome measures included sense of well-being, enjoyment of life, change in depression scale, laboratory nutrition parameters, energy intake counts, body composition, and adverse events.
  
  
  RESULTS
  At 12 weeks there were no significant differences in weight gain between treatment groups, whereas MA-treated patients reported significantly greater improvement in appetite, enjoyment of life, and well-being. Body composition was not statistically different between the two groups. At Week 25 (3 months after treatment), 61.9% of MA-treated patients had gained > or =1.82 kg (4 lbs) compared to 21.7% of placebo patients.
  
  
  CONCLUSIONS
  In geriatric patients with weight loss or low body weight MA improves appetite and well-being after 12 weeks of treatment. During the 3 months of MA treatment, there was no statistically significant weight gain (> or =4 lbs). Three months after treatment, weight gain (> or =4 lbs) was significantly increased in MA-treated patients.
authors.affiliation: VA Medical Center Northport, NY 11768-2290, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Yeh
authors.forename: S Y
authors.initials: SY
authors.lastname: Wu
authors.forename: T P
authors.initials: TP
authors.lastname: Lee
authors.forename: J S
authors.initials: JS
authors.lastname: Olson
authors.forename: M R
authors.initials: MR
authors.lastname: Stevens
authors.forename: T
authors.initials: T
authors.lastname: Dixon
authors.forename: R J
authors.initials: RJ
authors.lastname: Porcelli
authors.forename: M W
authors.initials: MW
authors.lastname: Schuster
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001066:Appetite / Q000187:drug effects; D001823:Body Composition; D001835:Body Weight / Q000187:drug effects; D002100:Cachexia / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006707:Homes for the Aged; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009518:New York; D009752:Nutritional Status; D011788:Quality of Life; D015431:Weight Loss
chemical_list: D019290:Megestrol Acetate